Gelonghui November 15 丨Yunnan Baiyao (000538.SZ) recently received a survey from institutional investors and said that in the first three quarters of 2023, the company invested 219 million yuan in R&D, an increase of 5.17% over the previous year. In terms of building R&D capacity, the company set up an R&D management committee to manage the overall R&D system, using the R&D ideas of inheriting the essence of Yunnan traditional Chinese medicine, empowering health product upgrades, careful layout of innovative drugs, and AI-assisted drug design to carry out unified resources and efficient management of resources. At the same time, the R&D project establishment and licensing system is scientifically clear, and diversification and advantages are focused in parallel, further strengthening the supervision and management of the company's scientific research and development.
云南白药(000538.SZ)：前三季度研发投入2.19亿元 同比上涨5.17%
Yunnan Baiyao (000538.SZ): R&D investment of 219 million yuan in the first three quarters increased 5.17% year-on-year
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.